We are live on ! Find out more
FOMX

Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX

Delisted

FOMX was delisted on the 6th of March, 2020.

58 hedge funds and large institutions have $68.5M invested in Foamix Pharmaceuticals Ltd. Ordinary Shares in 2019 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 17 increasing their positions, 20 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

6% less funds holding

Funds holding: 6258 (-4)

15% less repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 20

40% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 10

40% less capital invested

Capital invested by funds: $115M → $68.5M (-$46.6M)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
58
Holders Change
-4
Holders Change %
-6.45%
% of All Funds
1.26%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
6
Increased
17
Reduced
20
Closed
10
Calls
$41K
Puts
Net Calls
+$41K
Net Calls Change
-$434K

FOMX Hedge Fund Activity: Q2 2019 in Review

58 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) for Q2 2019, worth a combined $68.5M — down 40% from $115M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of FOMX and 6 opened new positions — a net loss of 4 holders — while 20 trimmed existing stakes and 17 added.

The largest buyer was DSC Advisors, adding an estimated $1.17M. The largest seller was Handelsbanken Fonder, exiting entirely with an estimated $2.55M sold.

  • 58 institutional investors held Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) as of Q2 2019, down from 62 in Q1 2019.
  • Funds reported $68.5M of Foamix Pharmaceuticals Ltd. Ordinary Shares stock for Q2 2019, down 40% quarter-over-quarter.
  • 6 funds opened new Foamix Pharmaceuticals Ltd. Ordinary Shares positions in Q2 2019 and 10 closed out, a net change of -4 holders.
  • The largest Foamix Pharmaceuticals Ltd. Ordinary Shares buyer in Q2 2019 was DSC Advisors, an estimated $1.17M added.
  • The largest Foamix Pharmaceuticals Ltd. Ordinary Shares seller in Q2 2019 was Handelsbanken Fonder, an estimated $2.55M sold.

Based on aggregated 13F filings for Q2 2019.